



200.0 126 Gp 186

part-Fin

IN THE UNITED STATES PATENT OFFICE

Application Serial No. 07/838,675

Our Ref.: PT-1039

Applicants: Rudolf Edgar Falk, and
Samuel Simon Asculai

Agent: Ivor M. Hughes
Suite 200
175 Commerce
Valley Dr., West,
Thornhill, Ontario
L3T 7P6

Title : TREATMENT OF DISEASE EMPLOYING
HYALURONIC ACID AND NSAIDS

Inventors : Rudolf Edgar Falk, and
Samuel Simon Asculai

Filed : February 21, 1992

Examiner : Mr. Stephen J. Martin, PhD

Group Art Unit: 1806

Due Date: January 14, 1995
(January 17, 1995)

January 13, 1995

The Commissioner of Patents,
UNITED STATES PATENT OFFICE,
2011 Jefferson Davis Highway,
Crystal Plaza, Room 1303
Arlington, Virginia
22202 U.S.A.

Dear Sir:

**SUPPLEMENTARY INFORMATION
DISCLOSURE STATEMENT**

Applicants and the undersigned are aware of "patents, publications, or other information" which they believe may be material to the examination of the above-identified application. Copies of these items were previously submitted to the Examiner with Application Serial No. 07/675,908 with the respective Response filed January 6,

RECEIVED
MAR 06 1995
GROUP 1500
GROUP 1800

1995 and are therefore not included with this Supplementary Information Disclosure Statement. In addition, one sheet of Form PTO-1449 listing them, are submitted herewith pursuant to 37 C.F.R. §§ 1.97-1.99 and to the duty of disclosure set forth in 37 C.F.R. § 1.56.

Although this Information Disclosure Statement identifies references which may be "material," it is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" (within the meaning of 35 U.S.C. § 102 103) as to the invention disclosed and claimed in this application unless specifically designated as such. Moreover, no representation is intended as to the relative relevance of any portion of the references or as to the relevance among references, whether cited in this Statement or elsewhere.

In accordance with 37 C.F.R. § 1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a novelty search has been made or that no other information which may be material (as defined in 37.C.F.R. § 1.56(a)) exists.

UNITED STATES PATENTS

USP 2,583,096
USP 3,436,454
USP 3,887,703
USP 4,272,522
USP 4,716,224
USP 4,853,226
USP 4,946,870

AUSTRALIAN PATENTS

AU-B-72117/87
AU 30806/84

EUROPEAN PATENTS

EP 0,378,852

GREAT BRITAIN

GB 1,283,892
GB 2,099,826-A

JAPANESE PATENTS

JP-A-116678/88
JP 61-233,622
JP 57-183,707

GERMAN PATENTS

DE 2,364,373

OTHER DOCUMENTS

Alaverdyan MI, Ter-Avetisyan AT.

Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemia.

Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.

Balazs EA, Gibbs DA.

The rheological properties and biological function of hyaluronic acid.

In: *Chemistry and Molecular Biology of the Intercellular Matrix. Volumes III.* New York: Academic Press, 1970. PP. 1241-1253.

Balazs EA, Band P.

Hyaluronic acid: Its structure and use.

Cosmetics & Toiletries . Polymers in Cosmetics 1984; 99: 65-72.

Camber O, Lundgren P.

Diffusion of some low molecular weight compounds in sodium hyaluronate.

Acta Pharmaceutica Suecica 1985; 22(6): 315-320.

Camber O, Edman P, Gurny R.

Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits.

Current Eye Research 1987; 6(6): 779-784.

Chang S-C.

Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit.

Dissertation Abstracts International 1988; 49(2): 367-B.

Cravioto, R.O., et al.

Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoïd From Vitreous Humor in Depressing Blood-Sugar Levels

Science (1950); Vol. 111: 520-521

Gieldanowski, Jerzy; Skowronska, Jadwiga

Studies on immunosuppressive and anti-inflammatory effect of adriamycin.

Arch. Immunol. Ther. Exp. (1980); 28 (3): 439-446

Hassan HG, Akerman B, Ranck H, Lindberg B, Lindquist B.
Effects of adjuvants to local anaesthetics on their duration.
Acta Anaesthesiol. Scand. 1985; 29: 384-388.

Hurd ER
Immunosuppressive and anti-inflammatory properties of cyclophosphamide, azathioprine and methotrexate.
Arthritis and Rheumatism (1973 Jan-Feb); 16 (1): 84-88

Idson B.
Polymers in skin cosmetics.
Cosmetics & Toiletries 1988; 103: 63-68.

Johansson A, Hassan H, Renck H.
Effects of adjuvants to local anaesthetics on their duration.
Acta Anaesthesiol. Scand. 1985; 29: 736-738.

Kalbhenn D.A.
The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthritis and its counteraction by a biological GAG-peptide complex (Rumalon®).
Z. Rheumatol (1982); 41: 202-211

Katsu M., Abe T., Shimada S.
Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence.
Nippon Rinsho (1968 Jan); 26(1): 89-95

Kreis H, Chkoff N, Droz D, et al.
Nonsteroid anti-inflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients.
Transplantation (1984 Feb.); 37(2): 139-145

McIlwraith W.
Current concepts in equine degenerative joint disease.
Journal of the American Veterinary Medical Association 1982; February 1: 239-250.

Mizushima Y.
Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future.

Nippon Rinsho (Jan. 1986); 26(1): 61-65

Nizolek DJH, White KK.

Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease: A review.

The Cornell Veterinarian 1981; 71(4): 355-375.

Pigman W, et al.

Acide hyaluronique et facteurs de perméabilité tissulaire.

Bull. Soc. Chim. Biol. 1963; 45(2-3): 185-202.

Pruett RC, Schepens CL, Constable IJ, Swann DA.

Hyaluronic acid vitreous substitute.

In: *Vitreous Surgery and Advances in Fundus Diagnosis and Treatment*. Freeman H.M., et al., Editors. Appleton-Century-Crofts, 1977: Chapter 55, pp. 433-444.

Reim M, Teping C.

Surgical procedures in the treatment of most severe eye burns.

Acta Ophthalmologica 1989-Supplementum 192; 67: 47-54.

Rydell NW, Balazs EA.

Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation.

Clinical Orthopaedics and Related Research (1971); 80(October): 25-29.

Saba P, Galeone F, Salvadorini F, Guarguaglini M, Ombrato M.

Investigation of the antihyperlipemic activity of an association of clofibrate and extractive mucopolysaccharide complex.

Current Therapeutic Research (1978); 23(4): 455-463.

Stegman R, Miller D.

Use of sodium hyaluronate in severe penetrating ocular trauma.

Acta Ophthalmol. (1986); 18: 9-13.

Trabucchi E, Foschi D, Marazzi M, Radaelli E, Lucianetti A, Rizzitelli E, Baratti C, et al.

Prevention of wound dehiscence in severely obese patients with jejunio-ileal by-pass: The role of hyaluronic acid.

Pharmatherapeutica (1988); 5(4): 233-239.

Sertoli P, Merello A, Parodi M.

L'acido ialuronico, per uso topico, nella cura delle ulcere trofo-circolatorie degli arti inferiori. (Comunicazioni).

Giornale Italiano di Dermatologia (1970); 45(8): 468-471.

Walther, M.

The Prevention of Striae Cutis Distansae During Pregnancy.

Mineva Gynecologia (1981); Vol. 33: 497-499


Weirich E.G., Longauer J.K., Kirkwood A.H.

Dermatopharmacology of salicylic acid. III. Topical contra-inflammatory effect of

salicylic acid and other drugs in animal experiments.

Dermatologica (1976); 152 (2): 87-99

Respectfully submitted,



Ivor M. Hughes,
Registration No. 27,759
Agent for Applicants